UndisclosedMergerHealthcare & Life Sciences
Pulmatrix holders approve Eos SENOLYTIX merger
Pulmatrix has received stockholder approval and SEC effectiveness for its merger with Eos SENOLYTIX, a private biotech developing peptides for aging-related diseases. Closing still depends on Nasdaq listing approval and a reverse stock split, and is expected by year-end.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →